Skip to main content
Medistim logo

Medistim — Investor Relations & Filings

Ticker · MEDI ISIN · NO0010159684 LEI · 5967007LIEEXZXJOX483 OL Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2017-08-09 Investor Presentation
Country NO Norway
Listing OL MEDI

About Medistim

https://medistim.com/

Medistim is a medical technology company specializing in intraoperative quality assessment solutions. A pioneer and market leader in Transit Time Flow Measurement (TTFM), the company develops and manufactures advanced medical devices for use during surgical procedures. Its flagship MiraQ™ system uniquely combines TTFM with high-frequency ultrasound imaging, providing surgeons with real-time data to verify graft function and blood flow. This technology is applied in cardiac, vascular, and transplant surgery to enhance procedural quality control and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Presentasjon av resultater for 2. kvartal og første halvår 2017 for Medistim ASA
Investor Presentation Classification · 95% confidence The document text is very short (506 characters) and announces a presentation regarding the results for the 2nd quarter and first half of 2017 for Medistim ASA. It specifies the date, time, and location of this presentation and lists the attending executives (CEO, CFO). This strongly suggests an announcement related to an earnings event, but it is not the full earnings release (ER) or the detailed interim report (IR). Since it is an announcement about a presentation of results, it most closely aligns with an Investor Presentation (IP) or potentially an Earnings Release (ER) announcement, but given the context of a 'presentation' being scheduled, IP is a strong candidate. However, since the content is about presenting the results for a specific period (Q2/H1 2017), it is fundamentally an announcement related to the release of periodic financial results. Given the options, and the focus on presenting the results, it is best classified as an Investor Presentation (IP) or potentially an Earnings Release (ER) announcement. Since it is an invitation to a presentation *following* the release of results, IP is the most fitting category for the presentation material itself, or if this is just the announcement of the presentation, it could be RPA. Given the content is about the presentation itself, IP is chosen over ER (which is usually the initial press release of figures).
2017-08-09 Norwegian
Presentation of second quarter and first half results for 2017 for Medistim ASA
Investor Presentation Classification · 95% confidence The document text explicitly states it is a 'Presentation of second quarter and first half results for 2017 for Medistim ASA' and invites attendees to a presentation event, listing the CEO and CFO who will present. This strongly indicates the document is related to the release of periodic financial results, but the text itself is an invitation/announcement about the presentation event, not the full results document or the transcript of the call. Given the options, this is most closely related to an Investor Presentation (IP) or potentially an Earnings Release (ER) announcement, but since it is an invitation to a presentation of results, 'Investor Presentation' (IP) is the most fitting category for the material being presented, or if interpreted as the announcement of the results presentation, it could lean towards ER or RPA. However, the content describes the event where the results will be presented, which aligns well with the nature of an Investor Presentation material being discussed. Given the short length and focus on the event details, it could also be an RPA, but the subject matter is clearly financial results presentation. I will classify it as Investor Presentation (IP) as it describes the event where the results presentation will occur.
2017-08-09 English
Medistim har mottatt klarering for salg av MiraQ i Kina
Regulatory Filings Classification · 100% confidence The document is a short announcement (3128 characters) in Norwegian stating that Medistim ASA has received clearance from the Chinese health authorities (CFDA) to sell its MiraQ product in China. It details the product, market opportunity, and includes quotes from the CEO. This is a specific, material event announcement that is not a full financial report (like 10-K or IR), nor is it a transcript, proxy statement, or dividend notice. It fits best as a general regulatory or material event announcement. Since it is a specific operational/market update that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard announcements, or potentially a general announcement if RNS is reserved strictly for exchange filings. Given the context of corporate filings, this is a material event disclosure. RNS (Regulatory News Service) is the standard category for such immediate, non-periodic disclosures in many European contexts, making it the best fit among the provided options for a specific, non-financial report announcement.
2017-08-09 Norwegian
Medistim has received clearance for sale of MiraQ in China
Regulatory Filings Classification · 100% confidence The document is a short announcement dated August 9th, 2017, from Medistim ASA regarding receiving clearance from the China Food and Drug Administration (CFDA) for selling its MiraQ product in China. It details the product, market opportunity, and includes contact information. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A/PSI). It announces a significant business/regulatory event related to market access and sales potential. Since it is a specific announcement about regulatory approval for a product in a new market, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory update that doesn't fit the other specific categories like M&A (TAR) or Capital Changes (CAP). Given its brevity and nature as a press release style announcement, RNS is the most appropriate fallback.
2017-08-09 English
Disclosure of voting rights in Medistim ASA
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses the disclosure of voting rights following a transaction where Danske Bank Group bought shares in Medistim ASA. This directly relates to changes in significant share ownership levels, as the transaction caused their holding to cross or change relative to a threshold (5.35% is mentioned). This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document is short (549 chars), but its content is a specific notification about shareholding changes, not just an announcement that a report is available.
2017-05-12 English
Mandatory notification of trade in Medistim ASA
Director's Dealing Classification · 100% confidence The document text explicitly states it is a 'Mandatory notification of trade' involving a 'Board member' (Lars Rønn) purchasing shares of Medistim ASA. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors), which is classified as Code: DIRS.
2017-04-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.